Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.

[1]  L. Skalniak,et al.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. , 2017, Angewandte Chemie.

[2]  Jiawei Wu,et al.  Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab , 2017, Oncotarget.

[3]  M. Davies,et al.  Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events , 2017, ImmunoTargets and therapy.

[4]  L. Skalniak,et al.  Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells , 2017, Oncotarget.

[5]  K. Zak,et al.  Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. , 2017, Structure.

[6]  T. Holak,et al.  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. , 2017, Journal of medicinal chemistry.

[7]  G. Gao,et al.  Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab , 2017, Protein & Cell.

[8]  Aiwu Zhou,et al.  Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade , 2017, Cell Discovery.

[9]  S. Almo,et al.  Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy , 2017, EBioMedicine.

[10]  S. Cavnar,et al.  The immuno-oncology race: myths and emerging realities , 2017, Nature Reviews Drug Discovery.

[11]  P. Plantin,et al.  Syndrome de Lyell aux anti-PD1 d’évolution fatale , 2017 .

[12]  Haiwei Song,et al.  Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab , 2016, Cell Research.

[13]  P. Plantin,et al.  [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome]. , 2017, Annales de dermatologie et de venereologie.

[14]  G. Gao,et al.  Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy , 2016, Cell Research.

[15]  S. Ryu,et al.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy , 2016, Nature Communications.

[16]  S. Iwata,et al.  High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1 , 2016, Scientific Reports.

[17]  A. Kruse,et al.  Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. , 2016, Structure.

[18]  K. Zak,et al.  Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015) , 2016, Expert opinion on therapeutic patents.

[19]  A. Mathew,et al.  A case of fatal Guillain–Barre syndrome from anti-PD1 monoclonal antibody use , 2016, Journal of Cancer Research and Clinical Oncology.

[20]  Tianhong Li,et al.  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy , 2016, Journal of Hematology & Oncology.

[21]  K. Zak,et al.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.

[22]  L. Jeffrey Medeiros,et al.  Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. , 2016, Biochimica et biophysica acta.

[23]  Zhaoqin Huang,et al.  Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. , 2015, Cancer treatment reviews.

[24]  K. Zak,et al.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. , 2015, Structure.

[25]  G. Scapin,et al.  Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab , 2015, Nature Structural &Molecular Biology.

[26]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Matteo Brunelli,et al.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.

[28]  Marawan Ahmed,et al.  Human PD-1 binds differently to its human ligands: a comprehensive modeling study. , 2015, Journal of molecular graphics & modelling.

[29]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[30]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[31]  Alexander Dömling,et al.  Programmed Death‐1: therapeutischer Erfolg nach über 100 Jahren Krebsimmuntherapie , 2014 .

[32]  A. Dömling,et al.  Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. , 2014, Angewandte Chemie.

[33]  Weiru Wang,et al.  Targeting protein-protein interaction by small molecules. , 2014, Annual review of pharmacology and toxicology.

[34]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[35]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[36]  S. Almo,et al.  Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 , 2008, Proceedings of the National Academy of Sciences.

[37]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[38]  D. Y. Lin,et al.  The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors , 2008, Proceedings of the National Academy of Sciences.

[39]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[40]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[41]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[42]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[43]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[44]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.